Texmaco Rail shares rally 8% on major export order from CAMALCO SA, Cameroon
The company received a Letter of Intent dated June 24, 2025, for a contract worth USD 62.24 million (approx. ₹535 crore). The deal includes manufacturing and supplying 560 open-top wagons valued at USD 32.76 million (₹282 crore), along with a 20-year maintenance contract worth USD 29.48 million (₹253 crore).
The wagons will be delivered in two phases over 24 months from the purchase order date. Additionally, the contract includes the potential for an extra 1,040 wagons to be supplied over the next five years, along with extended maintenance support.
This deal marks a major milestone in Texmaco's global expansion strategy and highlights the company's growing presence in international markets.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
3 hours ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
5 hours ago
- Yahoo
Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034
The global oligonucleotide CDMO market is valued at USD 3.11 billion in 2025 and is projected to reach approximately USD 18.37 billion by 2034, expanding at a CAGR of 21.83% over the forecast period. Ottawa, Aug. 08, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global oligonucleotide CDMO market size to grow from USD 2.55 billion in 2024 and is expected to expand USD 18.37 billion by 2034. The growth of the market is driven by the increased demand for specialized techniques, which are technologically advanced due to the growing prevalence of chronic diseases in the region. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the oligonucleotide CDMO market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. By service, the contract manufacturing segment led the market in 2024. By service, the contract development segment is estimated to achieve significant growth during the forecast period. By type, the ASO segment held a significant share of the market in 2024. By type, the siRNA segment is expected to grow significantly during the forecast period. By application, the therapeutic segment held the largest share of the oligonucleotide CDMO market in 2024. By application, the research segment is anticipated to grow at a significant rate during the forecast period. By end-use, the pharma segment held a major share of the market in 2024. By end-use, the biotech segment is anticipated to achieve a significant share of the market during the forecast period. Market Overview & Potential An oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in offering comprehensive services for developing and manufacturing short oligonucleotides, which are synthetic nucleic acid sequences used in various biotech and pharmaceutical applications. These organizations provide expertise in custom synthesis, process development, scale-up, and GMP manufacturing of oligonucleotides. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Growth Potential Responsible for The Growth of The Oligonucleotide CDMO Market? The growth of the market is driven by the growing demand for personalized medicines and RNA therapeutics, which demand specialized manufacturing capabilities, which fuels the growth of the market. The increasing prevalence of chronic diseases, especially cancer and cardiovascular diseases, with advancements in oligonucleotide manufacturing to improve synthesis technologies with automated techniques, drives the growth of the market. Other key growth drivers are government support and funding, increased investment in biotechnology, globalization, and increased collaboration boost the growth of the market. What Are the Emerging Trends in the Oligonucleotide CDMO Market? Growing Demand for Oligo-based Therapies: Oligonucleotides, including antisense oligonucleotides and small interfering RNAs, are increasingly recognized as therapeutic agents because of their targeted action and specificity. Focus on Precision Medicine: The shift toward personalized treatments designed for individual patients is boosting the need for specialized oligonucleotide therapies. Increased FDA Approvals: The rising number of FDA approvals for oligonucleotide-based drugs, such as Qalsody for ALS, further fuels market growth and stimulates innovation. Cost Efficiency and Expertise: Outsourcing to CDMOs enables companies to utilize specialized knowledge and potentially lower costs associated with in-house manufacturing, particularly for complex processes. What Are the Major Challenges Facing the Oligonucleotide CDMO Market? The market encounters several notable challenges, mainly due to manufacturing complexity, regulatory obstacles, and the need for advanced expertise and infrastructure. Scaling from research to commercial volumes, achieving high purity, and ensuring delivery efficiency to target sites are significant hurdles. Evolving regulatory requirements and the need for specialized skills in oligonucleotide synthesis, purification, and conjugation also contribute to the difficulty. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Insights Why Did North America Lead the Oligonucleotide CDMO Market in 2024? North America held a dominant position in 2024 due to its well-established research facilities, substantial R&D investments in peptide and oligonucleotide therapies, and a higher prevalence of chronic diseases. The demand for biopharmaceuticals like oligonucleotides and peptides supports this growth. North American CDMOs are well-equipped to meet this demand by providing specialized development and manufacturing services for these complex compounds. The market expansion is driven by ongoing investments from pharmaceutical and biotech firms into R&D, often through partnerships with CDMOs to access advanced infrastructure and expertise. High R&D investment, advanced biotech infrastructure, rising chronic disease prevalence, and strong pharmaceutical industry demand drive U.S. oligonucleotide CDMO growth. Regulatory clarity from the FDA, increasing personalized medicine focus, and government support for genomics research further enhance market expansion, fostering innovation and strategic collaborations with contract manufacturers. Government incentives for biotechnology, a skilled scientific workforce, and growing demand for precision medicine propel Canada's oligonucleotide CDMO sector. Strong academic-industry partnerships, supportive regulatory frameworks, and increasing investments from global pharma companies in Canadian CDMO facilities promote innovation, clinical trials, and manufacturing scalability within the country. Why Is Asia Pacific Projected to Show Rapid Growth in the Oligonucleotide CDMO Market? Asia Pacific is anticipated to be the fastest-growing region for oligonucleotide CDMOs during the forecast period. Countries like China, Japan, India, and South Korea are leading due to their large populations, focus on biopharmaceutical innovation, and strong healthcare investments. The region's market share has notably increased over recent years, supported by economic growth and rising prosperity, making it attractive for pharmaceutical outsourcing. This growth is further fueled by increased R&D funding and improvements in healthcare infrastructure. Rapid biotechnology expansion, government funding, and a large patient population fuel oligonucleotide CDMO growth in China. Domestic pharma companies increasingly outsource production, while favorable policies, infrastructure development, and cost advantages attract global partnerships. China's focus on RNA therapeutics and local innovation also accelerates CDMO sector maturation and competitiveness. Low manufacturing costs, a strong generic pharmaceutical base, and a growing talent pool drive India's oligonucleotide CDMO growth. Government initiatives supporting biotech innovation, rising contract research demand, and increased interest from Western firms in Indian CDMOs contribute. The expanding clinical trial ecosystem further enhances market attractiveness and outsourcing potential. Become a valued research partner with us - Segmental Insights Which Service Segment Dominated the Oligonucleotide CDMO Market in 2024? The contract manufacturing segment led the market in 2024, driven by the rising need for wide-scale, cGMP-compliant oligonucleotide APIs for clinical and commercial use. To meet the growing demand for ASOs, siRNAs, and mRNA-based therapies, CDMOs equipped with advanced solid-phase synthesis, automated fill-finish systems, and high-throughput purification are vital. This leadership is reinforced by pharmaceutical companies' reliance on CDMOs for high-purity, scalable, and globally compatible manufacturing solutions, driven by strict regulations and expansion challenges. This led to a growing and expanding influence on market growth. The contract development segment is estimated to achieve significant growth during the forecast period. Encompassing services like preclinical development, formulation, process development, and analytical techniques. These services are crucial for optimizing production processes and ensuring the safety and quality of oligonucleotides and peptides. R&D in oligonucleotide therapies is a key investment focus for pharma and biotech companies. Partnering with CDMOs allows these companies to reduce costs and accelerate product development, focusing on their core competencies. How did ASO Segment Dominated the Oligonucleotide CDMO Market in 2024? The ASO segment held a significant share of the market in 2024. Over the decades, the biotech and pharma industries have developed innovative approaches to target disease-related proteins, demanding innovation and development of new technologies and forms of products, which increases the demand for the market. RNA therapeutics, especially antisense oligonucleotides, have made significant progress in the market. Several ASO-based drugs are already FDA-approved, with many more under clinical testing. These factors support the growth and expansion of the market. The siRNA segment is expected to grow significantly during the forecast period. SiRNA technologies offer speed and specificity, helping to overcome preclinical drug development hurdles, which fuels the demand for the market. They currently assist in identifying the most promising pharmacological targets for specific diseases and are being explored for new, potent applications in drug candidate prioritization. These applications and benefits offered by the segment promote the growth and expansion of the market. Which Application Segment Dominated the Oligonucleotide CDMO Market in 2024? The therapeutic segment held the largest share of the market in 2024. Approaches have been developed to enhance the pharmacokinetics and pharmacodynamics of oligonucleotides. Historically targeted at rare diseases and niche markets, oligonucleotides now benefit large patient groups. The field is rapidly expanding despite fluctuations, with 44 companies having compounds in late-stage clinical trials or on the market. Major players include Johnson & Johnson, Roche, Novartis, and AstraZeneca, alongside specialized biotech firms like Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Concurrently, there has been notable activity in oligonucleotide patents and applications influencing the growth. The research segment is anticipated to grow at a significant rate in the oligonucleotide CDMO market during the forecast period, with contributions from research institutions impacting early-stage research, innovative technologies, and scientific breakthroughs. These institutions are vital in identifying therapeutic potentials, fostering partnerships with CDMOs and pharma companies, and influencing market dynamics. Advances in distribution, analytics, and synthesis are driving market expansion, and published research influences development and manufacturing strategies. How did the pharma Segment dominate the Oligonucleotide CDMO Market In 2024? The pharma segment accounted for a major market share in 2024. The advent of oligonucleotide therapies has revolutionized medicine, with several approved in the US and EU. These include a mix of single and double-stranded polydeoxyribonucleotides, six siRNAs, twelve ASOs, and one aptamer. The growing pharma sector and the application of oligonucleotides increase the demand for manufacturing and production, which contributes to the growth and expansion of the market. The biotech segment is also expected to claim a significant market share, enabled by protein-DNA functionalization through covalent bonding. This technology facilitates the creation of therapeutic molecules with potential applications for diseases like AIDS and cancer. The ongoing research and development in the biotech sector further propels the growth and expansion of the market. Recent Developments in the Oligonucleotide CDMO Market In April 2025, Sumitomo Chemical announced the launch of its new company, Sumitomo Chemical Advanced Medical Solutions America LLC, in Massachusetts to serve as its Oligonucleotide CDMO2 business. The company will provide gRNA samples to customers by August 2025. In July 2024, Agilent Technologies announced a strategic agreement to acquire BioVectra, a specialized CDMO, for $925 million. The acquisition was made to build Agilent Technologies' CDMO specialization in oligonucleotides and CRISPR therapeutics, expanding its portfolio of services and bringing world-class capabilities to support gene editing. Browse More Insights of Towards Healthcare: The global life science CDMO market is witnessing rapid expansion, with revenues projected to reach several hundred million dollars by the end of the forecast period (2025–2034). The veterinary CRO and CDMO market was valued at USD 7.17 billion in 2024, is expected to reach USD 7.77 billion in 2025, and is projected to climb to approximately USD 16.13 billion by 2034, growing at a CAGR of 8.43% during 2025–2034. The advanced therapy medicinal products (ATMP) CDMO market stood at USD 6.73 billion in 2024, increased to USD 7.99 billion in 2025, and is forecast to surge to USD 37.27 billion by 2034, registering a CAGR of 18.82% from 2025 to 2034. The investigational new drug CDMO market was valued at USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is anticipated to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% between 2025 and 2034. The mRNA therapeutics CDMO market was worth USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to grow to USD 13.63 billion by 2034, recording a CAGR of 11.37% during 2025–2034. The CDMO services for pharma and biotech market is experiencing substantial growth from 2024 to 2034, fueled by the increasing outsourcing trend among pharmaceutical and biotechnology companies. The CDMO aseptic filling solutions market is set for strong growth throughout the forecast period, driven by rising demand for sterile manufacturing capabilities and specialized injectable therapies. The active pharmaceutical ingredients (API) CDMO market was valued at USD 127.45 billion in 2024, increased to USD 136.92 billion in 2025, and is estimated to reach USD 260.98 billion by 2034, growing at a CAGR of 7.43% from 2025 to 2034. The small molecule CDMO market stood at USD 72.81 billion in 2024, rose to USD 78.01 billion in 2025, and is forecast to hit USD 145.12 billion by 2034, expanding at a CAGR of 7.14% during 2025–2034. The topical drugs CDMO market was worth USD 46.32 billion in 2024, increased to USD 51.62 billion in 2025, and is expected to reach USD 136.71 billion by 2034, registering a CAGR of 11.43% between 2025 and 2034. Top Companies and Their Contributions to the Market Contributions & Offerings to the Oligonucleotide CDMO Market Bachem A global leader in peptide and oligonucleotide synthesis, Bachem offers full CDMO services including development, GMP manufacturing, and analytics. Thermo Fisher Scientific Inc. Provides end-to-end oligonucleotide services, from preclinical to commercial scale, leveraging advanced technologies and global infrastructure. Agilent Technologies, Inc. Offers custom oligo synthesis and quality control platforms, supporting therapeutic development with scalable manufacturing capabilities. EUROAPI Delivers active pharmaceutical ingredient (API) production, including oligonucleotides, with a focus on quality, sustainability, and innovation. ST Pharm Specializes in large-scale GMP oligonucleotide manufacturing, supplying APIs globally with expertise in modified nucleic acids and cGMP compliance. Kaneka Eurogentec S.A. Provides custom manufacturing of therapeutic oligonucleotides, with cGMP-grade synthesis, formulation, and analytical support. Ajinomoto Co., Inc. Leverages proprietary biotechnologies for oligonucleotide production, offering scale-up and process development through its CDMO division. Aurigene Pharmaceutical Offers integrated CDMO services including oligonucleotide synthesis, analytical development, and GMP manufacturing for global biopharma clients. Syngene International Provides end-to-end oligo development and manufacturing, supporting early-stage to commercial scale with regulatory expertise. PolyPeptide Group Recently expanded into oligonucleotide CDMO services, combining peptide and oligo synthesis capabilities with advanced regulatory compliance. Key Players in Oligonucleotide CDMO Market Bachem Thermo Fisher Scientific Inc. Agilent Technologies, Inc. EUROAPI ST Pharm Kaneka Eurogentec S.A. Ajinomoto Co., Inc. Aurigene Pharmaceutical Services Ltd. Syngene International Limited PolyPeptide Group WuXi AppTec Eurofins Scientific GenScript Lonza Danaher Corporation Segments Covered in The Report By Service Contract Manufacturing Clinical Commercial Contract Development By Type ASO siRNA CPG Oligos gRNA By Application Therapeutic Research Diagnostics By End-User Pharma Biotech By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034
The U.S. pharmaceutical CDMO market is estimated at USD 39.14 billion in 2025 and is projected to reach approximately USD 68.57 billion by 2034, expanding at a CAGR of 6.43% over the forecast period. Ottawa, Aug. 13, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister firm of Precedence Research, the U.S. pharmaceutical CDMO market was valued at USD 36.77 billion in 2024 and is projected to reach approximately USD 68.57 billion by 2034, growing at a CAGR of 6.43%. The rising commercial scale-up in different therapeutic areas in the US and growing adoption of digital technologies are fueling overall market expansion. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways By product, the API segment dominated the U.S. pharmaceutical CDMO market in 2024 and is expected to grow fastest during the forecast period. By workflow, the commercial segment held the largest revenue share of the market in 2024. By application, the oncology segment registered dominance in the market in 2024. By end-use, the large pharmaceutical companies segment was dominant in the U.S. pharmaceutical CDMO market in 2024 and is expected to grow rapidly in the studies years. Market Overview & Potential Companies that are offering comprehensive services to different pharmaceutical and biotechnology companies, including both drug development and manufacturing in the US, are referred to as U.S. pharmaceutical CDMO market. Primarily, they provide expertise and resources for these companies. In 2025, they are focusing on novel drug discovery and development in oncology and other chronic conditions with the increased adoption of advanced production technologies. Moreover, the US is widely investing in robust and advanced infrastructure to fulfil the requirements of the increasing demand for specialized services, particularly in areas like biologics, sterile injectables, and gene and cell therapies. What are the Key Drivers Involved in The Growth of The Market? The U.S. pharmaceutical CDMO market has major dominating factors in its expansion, including crucial support to small and mid-sized pharmaceutical companies. These companies are facing the limitations of infrastructure for large-scale production with enhanced dependence on CDMOs for numerous stages of development and manufacturing. Also, benefits of pharmaceutical CDMOs, like scalability, flexibility, and cost-effectiveness, are fueling the expansion of the market with reduced capital investments. Besides this, experts working in CDMOs can navigate the complex regulatory landscape and check the compliance with standards like GMP (Good Manufacturing Practices). What are the Trends Associated with the U.S. Pharmaceutical CDMO Market? Different companies in the US are highly adopting outsourcing production to CDMOs to handle expenses and emphasis on competencies. Alongside, continuous advances in technologies and regulatory frameworks also play a crucial role in this market development. In May 2025, CDMO Piramal Pharma Solutions announced $90 million investment into its US manufacturing facilities. In March 2025, LGM Pharma, a global provider of customized API and CDMO services for the full drug product lifecycle, invested $6M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Emerging Challenge in the Market? Challenges connected with the U.S. pharmaceutical CDMO market include geopolitical stress, lack of raw material, and pandemic-related disturbances, are contribute as barriers in the production and delivery. Along with this, the rising need for a skilled workforce and specialized knowledge in continuous manufacturing and advanced bioprocessing demands vital investment in training and development. Country-level Analysis The U.S. pharmaceutical CDMO market is experiencing widespread expansion due to broader demand for a variety of biologics and biosimilars which are used in novel rare cases and other severe health issues. Besides this, ongoing technological breakthroughs in process chemistry and manufacturing automation are boosting the efficiency and quality of drug production, further propelling the adoption of CDMO services. As well as escalating cases of diverse cancers is assisting the development of novel cancer therapies, including targeted therapies and immunotherapies. For this market, In June 2025, Agenus Inc., a U.S.-based biotechnology company specializing in immuno-oncology, entered into a partnership with $141M Zydus investment to transform the immune-oncology area. Segmental Insights By product analysis How did the API Segment Lead the U.S. Pharmaceutical CDMO Market in 2024? The API segment was dominant in the market in 2024 and will grow rapidly during 2025-2034. An escalating demand for both traditional and complex APIs, especially in small molecule drugs, is fueling the segment's growth. In this segment, synthetic APIs experienced major demand, which are highly employed in numerous therapeutic areas such as cardiovascular, analgesic, and CNS drugs, making them an important driver in the API CDMO market. Also, this segment is moving towards continuous manufacturing, process analytical technology (PAT), sustainability, and digitalization, with enhanced focus on specialized CDMOs catering to niche therapeutic areas and expansion in biotech API development. Become a valued research partner with us - By workflow analysis What Made the Commercial Segment Dominant in the Market in 2024? In the U.S. pharmaceutical CDMO market, the commercial segment captured a major revenue share in 2024. Across the globe, one of the vital factors contributing to the overall market expansion is improved focus on the large-scale manufacturing of pharmaceuticals and biopharmaceuticals for commercial distribution. Moreover, widespread involvement of specialized expertise in biologics, cell & gene therapies, and mRNA vaccines necessitates sophisticated and specialized manufacturing capabilities. Additionally, CDMOs are boosting their service offerings by expanding collaboration with other organizations and companies to incorporate the complete drug development and manufacturing lifecycle, from early development to commercial launch. By application analysis How did Oncology Dominate the U.S. Pharmaceutical CDMO Market in 2024? The oncology segment registered dominance with the biggest share of the market in 2024. Eventual growth in cancer cases, with the progression of personalized therapies and targeted treatments, is impacting segment expansion. US CDMOs are stepping towards the transformation of advanced therapies, especially cell and gene therapies, antibody-drug conjugates, and bispecific antibodies, which are a major part of oncology clinical trials. These therapies are widely propelling demand for specialized facilities and expertise in handling potent APIs, cytotoxic compounds, and sterile injectables. By end-use analysis How did the Large Pharmaceutical Companies Hold a Major Share of The Market in 2024? The large pharmaceutical companies segment led the U.S. pharmaceutical CDMO market in 2024 and is anticipated to witness the fastest growth during 2025-2034. Nowadays, a rise in innovation investments, mainly in data analytics and AI, is assisting overall drug development processes and ultimately enhancing productivity. Apart from this, these companies are focusing on the utilization of advanced formulation technologies in specific areas, especially oral peptide formulations and permeation enhancers, to optimize drug delivery. These companies frequently grasp their robust infrastructure, scientific expertise, and global networks, which make them attractive for further collaborations and outsourcing to CDMOs in the US. Get the latest insights on healthcare industry segmentation with our Annual Membership: Ongoing Developments in the U.S. Pharmaceutical CDMO Market In July 2025, ESTEVE acquired Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), to accelerate its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US. In May 2025, Purdue University and a collaboration of leaders in AI, pharmaceutical manufacturing, and public policy launched a national effort in the Dirksen Senate Office Building to boost pharmaceutical manufacturing in the United States by revealing cutting-edge AI and advanced manufacturing technologies. In May 2025, Benuvia Operations, LLC, a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier, signed a multi-year supply agreement with a prominent U.S. pharmaceutical company to support the company's product development activities. Key Players in the U.S. Pharmaceutical CDMO Market Adare Pharma Solutions AGC Biologics Agilent Technologies Catalent Pharma Solutions Exela Pharma Sciences PCI Pharma Services Pfizer CentreOne Scorpius BioManufacturing Sharp Services Single Use Support Thermo Fisher Scientific UPM Pharmaceuticals, Inc. Browse More Insights of Towards Healthcare: The global bioconjugation market reached USD 5.52 billion in 2024, rose to USD 6.37 billion in 2025, and will likely hit USD 23.18 billion by 2034, expanding at a CAGR of 15.46% from 2025 to 2034. The U.S. residual DNA testing market continues its upward trajectory and is set to generate substantial revenue growth, potentially reaching hundreds of millions by 2034. The worldwide life science CDMO market is expanding significantly and is projected to record several hundred million dollars in additional revenue by the end of the forecast period from 2025 to 2034. The global veterinary CRO and CDMO market stood at USD 7.17 billion in 2024, increased to USD 7.77 billion in 2025, and will likely reach USD 16.13 billion by 2034, growing at a CAGR of 8.43% between 2025 and 2034. The global investigational new drug CDMO market measured USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is forecast to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% during the same period. The global advanced therapy medicinal products CDMO market stood at USD 6.73 billion in 2024, grew to USD 7.99 billion in 2025, and will likely surge to USD 37.27 billion by 2034, posting a CAGR of 18.82% between 2025 and 2034. The global mRNA therapeutics CDMO market valued at USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37% from 2025 to 2034. The CDMO services for pharma and biotech market is posting substantial growth from 2024 to 2034, fueled by rising outsourcing trends among pharmaceutical and biotech companies. The CDMO aseptic filling solutions market is recording robust growth and will continue booming through the forecast period, driven by growing demand for sterile manufacturing and specialized injectable therapies. The active pharmaceutical ingredients CDMO market stood at USD 127.45 billion in 2024, rose to USD 136.92 billion in 2025, and is projected to reach USD 260.98 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. Segments Covered in The Report By Product API Type Traditional API Highly Potent API Antibody-drug conjugate (ADC) Others Synthesis Synthetic Solid Liquid Biotech Drug Innovative Generics Manufacturing Continuous Manufacturing Batch Manufacturing Drug Product Oral Solid Dose Semi-Solid Dose Liquid Dose Others By Workflow Commercial Clinical By Application Oncology Small Molecules Biologics Infectious Diseases Neurological Disorders Cardiovascular Disease Metabolic Disorders Autoimmune Diseases Respiratory Diseases Ophthalmology Gastrointestinal Disorders Hormonal Disorders Hematological Disorders Others By End-Use Large Pharmaceutical Companies Medium Pharmaceutical Companies Small Pharmaceutical Companies Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
